NCT01162031撤回2 期
Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Assess the clinical activity, as represented by the overall response rate (complete response + partial response), of bortezomib in patients with relapsed or refractory T-cell prolymphocytic leukemia (PLL)
研究概览
简要总结
We hope to learn more about the clinical efficacy of bortezomib in T-cell prolymphocytic leukemia. Patients will be selected as a possible participant in this study because they have a bone marrow disorder known as T-cell prolymphocytic leukemia (T-cell PLL) which does not tend to respond well to conventional treatment with chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- •Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
- •Male subject agrees to use an acceptable method for contraception for the duration of the study.
- •Bilirubin: <2.0 x Upper limit of normal (ULN)/ Alanine Transaminase (ALT): <3.0 x ULN (<5x ULN if hepatic compromise is present).
- •Eastern Cooperative Group (ECOG) 0-
- •Confirmed diagnosis of T-cell PLL according to the WHO classification.
- •Confirmed prior therapy to which the subject was documented to be either refractory or has relapsed since treatment and first documented response.
排除标准
- •Patients meeting any of the following exclusion criteria are not to be enrolled in the study.
- •Patient has a platelet count of <30' 10 9/L within 14 days before enrollment.
- •Patient has an absolute neutrophil count of <1.0 ´ 10 9/L within 14 days before enrollment.
- •Patient has ³Grade 2 peripheral neuropathy within 14 days before enrollment.
- •Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
- •Patient has hypersensitivity to bortezomib, boron or mannitol.
- •Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum b-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
- •Patient has received other investigational drugs with 14 days before enrollment.
- •Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- •Patients with uncontrolled intercurrent illness, active or uncontrolled infections, or a fever >38.5c on the day of scheduled dosing.
- •Patients with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator's opinion, would be likely to interfere with a patient's participation in the study, or with the interpretation of the results.
- •Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc) that, in the judgment of the investigator, may affect the patient's ability to sign the informed consent and undergo study procedures.
- •Any condition that will put the patient at undue risk or discomfort as a result of adherence to study procedures.
结局指标
主要结局
Assess the clinical activity, as represented by the overall response rate (complete response + partial response), of bortezomib in patients with relapsed or refractory T-cell prolymphocytic leukemia (PLL)
时间窗: 1 year
次要结局
- prolymphocytic leukemia (PLL)(1 year)
- Evaluate time to progression in patients with T-cell prolymphocytic leukemia (PLL)(1 year)
- Evaluate the 1-year progression free survival (PFS), and 1-year overall survival (OS) in patients with T-cell prolymphocytic leukemia (PLL) treated with Velcade compared to historical controls(1 year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host DiseaseChronic Graft Versus Host DiseaseNCT00815919Dana-Farber Cancer Institute22
已完成
2 期
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerNCT00023712National Cancer Institute (NCI)58
已完成
2 期
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaMultiple MyelomaNCT00431769Janssen-Cilag International NV130
Unknown
2 期
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)Chronic Graft-versus-host DiseaseNCT01158105Baylor Research Institute25
终止
2 期
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung CancerSTAGE IIIB OR IV NON-SMALL CELL LUNG CANCERNCT00346645Gustave Roussy, Cancer Campus, Grand Paris46